Angiotensin-(1–7) suppresses hepatocellular carcinoma growth and angiogenesis via complex interactions of angiotensin II type 1 receptor, angiotensin II type 2 receptor and mas receptor

Molecular Medicine

Volumn 21, Issue , 2015, Pages 626-636

  Liu, Yanping ^a,b   Li, Bin ^b   Wang, Ximing ^b   Li, Guishuang ^a   Shang, Rui ^a   Yang, Jianmin ^a   Wang, Jiali ^a   Zhang, Meng ^a   Chen, Yuguo ^a   Zhang, Yun ^a   Zhang, Cheng ^a   Hao, Panpan ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN [1-7]; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; MAS RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; RECEPTOR; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); MITOGEN ACTIVATED PROTEIN KINASE 11; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AT1R GENE; AT2R GENE; CANCER GROWTH; CANCER INHIBITION; CELL COMMUNICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TREATMENT OUTCOME; TUMOR VOLUME; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEP-G2 CELL LINE; HUMAN; LIVER NEOPLASMS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHOSPHORYLATION;

ANGIOTENSIN I; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 11; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84948766690     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2015.00022     Document Type: Article

References (62)

1. George AJ, Thomas WG, Hannan RD. (2010) The renin angiotensin system and cancer: Old dog, new tricks. Nat. Rev. Cancer. 10:745-59.
2. Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millán S, Sánchez-Corona J. (2015) The renin-angiotensin system meets the hallmarks of cancer. J. Renin Angiotensin Aldosterone Syst. 16:227-33.
3. Chauhan VP, et al. (2013) Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4:2516.
4. Sevá Pessôa B, et al. (2013) Key developments in renin-angiotensin-aldosterone system inhibition. Nat. Rev. Nephrol. 9:26-36.
5. Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA. (2009) Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol. Cancer Ther. 8:1676-83.
6. Krishnan B, et al. (2013) Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate. 73:71-82.
7. Hao PP, et al. (2014) Evaluation of (131)I-anti-angiotensin II type 1 receptor monoclonal antibody as a reporter for hepatocellular carcinoma. PLoS One. 9:e85002.
8. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. (2002) Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. 51:1938-48.
9. Cook KL, Metheny-Barlow LJ, Tallant EA, Gallagher PE. (2010) Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res. 70:8319-28.
10. Hida T, et al. (1989) Chemosensitivity and radiosensitivity of small cell lung cancer cell lines studied by a newly developed 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) hybrid assay. Cancer Res. 49:4785-90.
11. Herrera M, Sparks MA, Alfonso-Pecchio AR, Harrison-Bernard LM, Coffman TM. (2013) Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein. Hypertension. 61:253-8.
12. Hafko R, et al. (2013) Commercially available angiotensin II At2 receptor antibodies are nonspecific. PLoS One. 8:e69234.
13. Michel MC, Wieland T, Tsujimoto G. (2009) How reliable are G-protein-coupled receptor antibodies? Naunyn Schmiedebergs Arch. Pharmacol. 379:385-8.
14. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. (2013) Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: New players of the renin-angiotensin system. J. Endocrinol. 216:1-17.
15. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. (2010) Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 30:1606-13.
16. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. (1996) Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension. 28:104-8.
17. Tallant EA, Ferrario CM, Gallagher PE. (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes though activation of the mas receptor. Am. J. Physiol. Heart Circ. Physiol. 289:H1560-6.
18. McCollum LT, Gallagher PE, Tallant EA. (2012) Angiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts. Peptides. 34:380-8.
19. Heringer-Walther S, et al. (2009) Angiotensin- (1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica. 94:857-60.
20. Rhodes DR, et al. (2009) AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc. Natl. Acad. Sci. U. S. A. 106:10284-9.
21. Suganuma T, et al. (2005) Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumour invasion, angiogenesis, and peritoneal dissemination. Clin. Cancer Res. 11:2686-94.
22. Lewandowska U, Lachowicz-Ochędalska A, Domińska K, Kaszewska D, Rębas E. (2011) Angiotensin II as a factor modulating protein tyrosine kinase activity in two breast cancer lines - MCF-7 and MDA-MB-231. Endokrynol. Pol. 62:151-8.
23. Zhao Y, et al. (2010) Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF- 7 breast cancer cells survival via PI3-kinase/Akt pathway. J. Cell Physiol. 225:168-73.
24. Fujiyama S, et al. (2001) Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin- 2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ. Res. 88:22-9.
25. Du H, et al. (2013) Effects of angiotensin II type 2 receptor overexpression on the growth of hepatocellular carcinoma cells in vitro and in vivo. PLoS One. 8:e83754.
26. Hu F, Morrissey P, Yao J, Xu Z. (2004) Development of AT(1) and AT(2) receptors in the ovine fetal brain. Brain Res. Dev. Brain Res. 150:51-61.
27. Menon J, et al. (2007) Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice though a reduction in cyclooxygenase-2. Cancer Res. 67:2809-15.
28. Gallagher PE, Tallant EA. (2004) Inhibition of human lung cancer cell growth by angiotensin- (1-7). Carcinogenesis. 25:2045-52.
29. Li H, et al. (2009) Angiotensin type 2 receptormediated apoptosis of human prostate cancer cells. Mol. Cancer Ther. 8:3255-65.
30. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. (2011) Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 25:2559-72.
31. Jiao H, et al. (2012) Human amniotic membrane derived-mesenchymal stem cells induce C6 glioma apoptosis in vivo though the Bcl-2/caspase pathways. Mol. Biol. Rep. 39:467-73.
32. Srivastava MK, et al. (2012) Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One. 7:e40677.
33. Holmgren L, O'Reilly MS, Folkman J. (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1:149-53.
34. Schmaltz C, Hardenbergh PH, Wells A, Fisher DE. (1998) Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol. Cell. Biol. 18:2845-54.
35. Feng Y, et al. (2010) The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol. Rep. 23:941-8.
36. Bağışlar, GS. (2009) Genetic and Epigenetic Analysis of Immortal and Senescence Arrested Liver Cancer Cells [dissertation]. Ankara (Turkey): Bilkent University. [cited 2015 Oct 26]. Available from: http://www.thesis.bilkent.edu.tr/0006157.pdf.
37. Cao Y, et al. (2011) Forty-year journey of angiogenesis translational research. Sci. Transl. Med. 3:114rv3.
38. Soto-Pantoja DR, Petty WJ, Gallagher PE, Tallant EA. (2009) Angiotensin-(1-7) inhibits triple negative tumor growth though the inhibition of angiogenesis and a reduction in placental growth factor PIGF [abstract]. Cancer Res. 69:s103.
39. Lin CY, et al. (2013) MiR-1 and miR-206 target different genes to have opposing roles during angiogenesis in zebrafish embryos. Nat. Commun. 4:2829.
40. Dvorak HF. (2002) Vascular permeability factor/ vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20:4368-80.
41. Krishnan B, Torti FM, Gallagher PE, Tallant EA. (2013) Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate. 73:60-70.
42. Ambati BK, et al. (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature. 443:993-7.
43. Harris AL. (2002) Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2:38-47.
44. Berra E, et al. (2000) Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem. Pharmacol. 60:1171-8.
45. Tallant EA, Clark MA. (2003) Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension. 42:574-9.
46. Tudisco L, et al. (2014) Epigenetic control of hypoxia inducible factor-1α-dependent expression of placental growth factor in hypoxic conditions. Epigenetics. 9:600-10.
47. Petty WJ, et al. (2012) Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of in vascular sarcomas. BMC Cancer. 12:404.
48. Patel N, Kalra VK. (2010) Placenta growth factorinduced early growth response 1 (Egr-1) regulates hypoxia-inducible factor-1alpha (HIF-1alpha) in endothelial cells. J. Biol. Chem. 285:20570-9.
49. Fischer C, et al. (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 131:463-75.
50. Hedlund EM, et al. (2013) Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc. Natl. Acad. Sci. U. S. A. 110:654-9.
51. Yang X, et al. (2013) Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc. Natl. Acad. Sci. U. S. A. 110:13932-7.
52. Jones MK, et al. (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5:1418-23.
53. Gately S, Li WW. (2004) Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol. 31:2-11.
54. Iñiguez MA, Rodríguez A, Volpert OV, Fresno M, Redondo JM. (2003) Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol. Med. 9:73-8.
55. Miyata Y, et al. (2003) Expression of cyclooxygenase- 2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res. 9:1741-9.
56. Röcken C, et al. (2007) The angiotensin II/ angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol. Biomarkers Prev. 16:1206-12.
57. Kosaka T, et al. (2010) Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer. Prostate. 70:162-9.
58. Clere N, et al. (2010) Deficiency or blockade of angiotensin II type 2 receptor delays tumourigenesis by inhibiting malignant cell proliferation and angiogenesis. Int. J. Cancer. 127:2279-2291.
59. Zhao W, Zhao T, Chen Y, Sun Y. (2015) Angiotensin 1-7 promotes cardiac angiogenesis following infarction. Curr. Vasc. Pharmacol. 13:37-42.
60. Cao Y. (2014) VEGF-targeted cancer therapeuticsparadoxical effects in endocrine organs. Nat. Rev. Endocrinol. 10:530-9.
61. Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK. (2001) Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk- 1/KDR in hepatocellular carcinoma. Am. J. Clin. Pathol. 116:838-45.
62. Choi WW, et al. (2005) Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod. Pathol. 18:143-52.